RecruitingNot a traditional drug phaseobservationalRules rewrite

A Prospective Study of Anxiety, Depression, and Bipolar Disorder in People

This study aims to understand how anxiety disorders, depressive disorders, and bipolar disorder change over time and to identify patterns that may help with earlier recognition, diagnosis, and prediction of future symptoms. The study will enroll approximately 2,690 participants aged 12 to 55 years across multiple hospitals in China.

Official registry: https://clinicaltrials.gov/study/NCT07903246 · Second Affiliated Hospital, Zhejiang University, School of Medicine · enrollment listed as 2,690

What this phase means

This is an observational study. You are not assigned a new experimental drug. Researchers measure what already happens in your care or in daily life.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

This listing is observational (StudyType). The registry does not assign a new experimental drug as the study intervention.

They plan to enroll about 2,690 people at Hangzhou. Taking part typically means study visits and measurements plus check-ins.

Official title (unrewritten)

A Prospective Cohort Study of Emotion-Related Disorders

Primary outcome (registry wording): Macro-Averaged Area Under the ROC Curve of the Multimodal Digital Phenotyping-Based Diagnostic Model in the Independent Validation Cohort

Who it is for (from inclusion criteria)

Ages 12 Years to 55 Years
General criteria for all groups:
Age 12 to 55 years, inclusive, of any sex
Education at or above the third-grade primary school level
Anxiety disorders group:
Meet DSM-5 diagnostic criteria for one or more anxiety spectrum disorders
Hamilton Anxiety Rating Scale (HAMA-14) total score of at least 14
Normal intellectual functioning, vision, and hearing

Who the registry excludes

The following criteria apply to all groups:
Failure to meet the who can join for the relevant group, or meeting DSM-5 criteria for a mental disorder other than those targeted by this study
Current risk of dangerous behavior, rated as level 2 or above on the dangerousness assessment specified in the protocol
Severe agitation, oppositional behavior, or markedly reduced volition or activity that prevents completion of the assessments
Current or previous organic brain disease, a history of epilepsy, or a history of traumatic brain injury
A history of drug or substance abuse, including tobacco, alcohol, or other psychoactive substances
Cardiovascular, cerebrovascular, respiratory, or neurological disease; infectious disease; other serious physical illness; or a pathological condition that may cause cognitive impairment

Public study contact (from the registry)

Ming Zheng, PhD

+8619550211701

mingzheng17@hotmail.com

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

1 listed

The Second Affiliated Hospital, School of Medicine, Zhejiang University — Hangzhou, Zhejiang, China (recruiting)

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseBethesda, Maryland

Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Re…

We will investigate the clinical manifestations and molecular genetic defects of heritable urologic malignant disorders. Families with urologic malignancy with known or suspected genetic basis will be enrolled.

NCT00001238 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)

RecruitingNot a traditional drug phaseBethesda, Maryland

Study of Systemic Lupus Erythematosus

This protocol will evaluate patients with systemic lupus erythematosus (SLE) and their relatives to learn more about how the disease develops and changes over time. It will also study genetic factors that make a person susceptible to SLE.

NCT00001372 · Official ClinicalTrials.gov record · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

RecruitingNot a traditional drug phaseWashington D.C., District of Columbia

Familial Mediterranean Fever and Related Disorders: Genetics and Disease Characteristics

This study is designed to explore the genetics and pathophysiology of diseases presenting with intermittent fever, including familial Mediterranean fever, TRAPS, hyper-IgD syndrome, and related diseases. The following individuals may be eligible for this natural history study: 1) patients with known or suspected familial Mediterranean fever, TRAPS, hyper-IgD syndrome or related disorders; 2) relatives of these patients; 3) healthy, normal volunteers 7 years of age or older.

NCT00001373 · Official ClinicalTrials.gov record · National Human Genome Research Institute (NHGRI)

FAQ about this NCT record

Is NCT07903246 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07903246?

Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07903246?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary